Industrialized GMP Production of CD34<sup>+</sup> Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.

Hénon, Philippe; Kowalczyk, Marc; Aries, Anne; Vignon, Christine; Trébuchet, Guillaume; Lahlil, Rachid

Industrialized GMP Production of CD34⁺ Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.

Hénon, Philippe; Kowalczyk, Marc; Aries, Anne; Vignon, Christine; Trébuchet, Guillaume; Lahlil, Rachid.

Afiliação

Hénon P; CellProthera SAS, 12 Rue du Parc, Mulhouse, France.
Kowalczyk M; CellProthera SAS, 12 Rue du Parc, Mulhouse, France.
Aries A; Institut de Recherche en Hématologie et Transplantation, Hôpital du Hasenrain, 87 Avenue d'Altkirch, Mulhouse, France.
Vignon C; CellProthera SAS, 12 Rue du Parc, Mulhouse, France.
Trébuchet G; CellProthera SAS, 12 Rue du Parc, Mulhouse, France.
Lahlil R; Institut de Recherche en Hématologie et Transplantation, Hôpital du Hasenrain, 87 Avenue d'Altkirch, Mulhouse, France.

Stem Cell Rev Rep ; 18(5): 1614-1626, 2022 06.

Article em En | MEDLINE | ID: mdl-35420389

Assuntos

Infarto do Miocárdio; Isquemia Miocárdica; Antígenos CD34/metabolismo; Células-Tronco Embrionárias/metabolismo; Humanos; Infarto do Miocárdio/terapia; Projetos Piloto; Medicina Regenerativa/métodos

Palavras-chave

CD34+ cells; Cell expansion; Heart diseases; Industrialization; ProtheraCytes®; Regenerative medicine; VSELs

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Isquemia Miocárdica / Infarto do Miocárdio Limite: Humans Idioma: En Revista: Stem Cell Rev Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google